AGP Executive Report
Last update: 9 hours agoAbortion Access in Liechtenstein: A new report highlights how Liechtenstein’s very strict abortion ban forces many people to travel abroad, with an information ban and lingering fear of legal risk even after 2015 changes. Rare Disease Treatment in Europe: Acadia’s DAYBU (trofinetide) has received European Commission approval as the first and only EU-authorised treatment for Rett syndrome neurobehavioral symptoms for patients aged five and up, though pricing and reimbursement deals still need to be worked out country by country. Breast Cancer Drug Expansion: The European Commission has authorized Gilead’s Trodelvy plus Merck’s Keytruda for first-line PD-L1-positive metastatic triple-negative breast cancer, including Liechtenstein, expanding options across PD-L1 status. Kidney Transplant Drug Watch: Hansa Biopharma is considering a potential U.S. Nasdaq listing as the FDA is expected to rule on its kidney transplant drug imlifidase later this year. Care Support for Residents: Lower Austria’s €1,000 Pflege- und Betreuungsscheck is open for 2026, with eligibility tied to residence status and care needs—not Austrian citizenship alone. Border Rules Explained: Coverage revisits how Schengen’s internal border-free travel relates to EU free movement, as some countries reintroduce checks.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
